Cabergoline-induced tricuspid regurgitation: Case report and review of literature
The increased risk of cardiac valve disease in patients treated for Parkinson′s disease with cabergoline has raised concerns about the safety of treatment with ergot-derived dopamine agonists in patients with endocrine diseases, especially prolactinoma. Concern is raised because the use of cabergoli...
Main Authors: | Mohammad Hayat Bhat, Syed Mushtaq, Sameena Saba, Riyaz Saif, Gazanfar Ali |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2011-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=2;spage=137;epage=139;aulast=Bhat |
Similar Items
-
No link to cardiac valvulopathy was seen in cabergoline treated patients
by: K Dharshini, et al.
Published: (2012-10-01) -
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
by: Shruti Khare, et al.
Published: (2017-01-01) -
Clinical and Hormonal Criteria of the Effectiveness of Suppressive Cabergoline Therapy in Patients with Organic Hyperprolactinemia
by: O.O. Khyzhniak, et al.
Published: (2015-10-01) -
Early Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
by: Youngki Lee, et al.
Published: (2014-09-01) -
The Conundrum of Tricuspid Regurgitation Grading
by: Yun Yun Go, et al.
Published: (2018-11-01)